Joseph Healey, PhDConsultant
Synthetic Biology, Drug Delivery & Venture Building

areas of expertise
- Synthetic biology/molecular biology and informatics — synthetic biologist with expertise in molecular biology, genomics, bioinformatics, particularly as applied to biologic drug development/discovery
- Preclinical development — expertise in the planning and execution of innovative research for new therapeutic modalities in the biologics and platform technology space, from earliest proof of concept to pre-clinical and IND-enabling studies.
- Biotech company building — founding and scaling new ventures, including securing significant capital, narrative/strategy positioning and operations (including fractional/interim leadership)
- Life sciences venture — Extensive due diligence and pitching experience, having raised significant venture capital as a founder and CEO; with investor “buy side” experience as venture partner
- Strategic advisory — advising government, research councils, and industry on engineering biology, innovation policy, and the translation of deep-tech life science platforms.
- Business development & partnering — sourcing, structuring and negotiating research collaborations and licensing arrangements with global pharmaceutical companies.
education
- Ph.D. in Mathematical Biology and Biophysical Chemistry – University of Warwick
- M.Sc. in Mathematical Biology and Biophysical Chemistry – University of Warwick
- BSc (Hons) in Biology – Aberystwyth University
Joseph Healey is a synthetic biologist and biotech entrepreneur with a track record of building deep-tech life science companies from the ground up. He is the founder of NanoSyrinx, a University of Warwick spinout developing engineered bacterial “nanosyringes” for intracellular protein delivery. Under his leadership as CEO and subsequently as CTO, the company raised approximately £20M from investors including Eli Lilly, Merck Ventures, Octopus Ventures, and BGF, and established sizeable collaborations including R&D evaluations with large pharma, and GMP manufacturing partnerships with CDMOs. Joe developed NanoSyrinx’s core technology during his PhD, and is an inventor on multiple key patent filings. After spinning the company out of academia, Joe oversaw its growth for approximately 6 years, with responsibility for everything from fundraising, budgeting, hiring strategy, product development/positioning and more.
NanoSyrinx’s platform enables the precise delivery of therapeutic proteins directly into target cells, addressing a fundamental limitation in biologics drug development. Joe’s work spans the full translational arc, from structural and molecular biology through to target cell engineering, partner-facing science, and commercial strategy. Based on his experience at NanoSyrinx, Joe has particular expertise in prelinical development of biologics, drug delivery and the platform biotech business model.
Beyond NanoSyrinx, Joe serves as a Venture Partner at Saras Capital, a UK early-stage VC focused on the convergence of technology and biology, where he applies his experience in deep-tech company building to investment evaluation and portfolio support. He is also a member of DSIT’s Engineering Biology Advisory Panel, a BBSRC Pool of Experts reviewer, and an Invited Lecturer at Warwick Medical School.
Joe holds a PhD in Synthetic and Molecular Microbiology from the University of Warwick and is based in the West Midlands.
Get in touch
If you’d like a free consultation, please start by completing the form: